Correlations between Janus Kinase 2 V617F Allele Burdens and Clinicohematologic Parameters in Myeloproliferative Neoplasms
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: This study evaluated potential correlations between the allele burden of the Janus kinase 2 (JAK2) V617F mutation and clinicohematologic characteristics in patients with myeloproliferative neoplasms (MPN). Methods: Clinical and hematologic features were reviewed for 103 MPN patients, including patients with polycythemia vera (PV, 22 patients), essential thrombocythemia (ET, 64 patients), and primary myelofibrosis (PMF, 17 patients). JAK2 V617F allele status and allele burdens were measured by allele-specific PCR and pyrosequencing, respectively. Results: The JAK2 V617F mutation was detected in 95.5%, 68.8%, and 52.9% of PV, ET, and PMF patients, respectively. JAK2 V617F-positive ET patients were significantly older and exhibited higher neutrophil fractions, a higher frequency of thrombotic events, and a higher myelofibrosis rate than JAK2 V617F-negative patients (P <0.05). PV patients carried the highest mean T allele burden (66.0%±24.9%) compared with ET (40.5%±25.2%) and PMF patients (31.5%±37.0%) (P =0.00). No significant correlations were detected between V617F allele burden and patient age, white blood cell count, Hb, Hct, or the platelet count for PV, ET, or PMF patients. ET patients with organomegaly had a higher JAK2 V617F allele burden (53.4%±23.7%) than patients without organomegaly (35.6%± 24.3%) (P =0.03). Conclusions: The JAK2 V617F mutational status and its allele burden correlate with the clinicohematologic phenotypes of ET patients, including older age, higher neutrophil count, and greater rates of organomegaly, thrombotic events, and myelofibrosis. For PV and PMF patients, larger-scale studies involving more MPN patients are needed.
Abstract
Background: This study evaluated potential correlations between the allele burden of the Janus kinase 2 (JAK2) V617F mutation and clinicohematologic characteristics in patients with myeloproliferative neoplasms (MPN). Methods: Clinical and hematologic features were reviewed for 103 MPN patients, including patients with polycythemia vera (PV, 22 patients), essential thrombocythemia (ET, 64 patients), and primary myelofibrosis (PMF, 17 patients). JAK2 V617F allele status and allele burdens were measured by allele-specific PCR and pyrosequencing, respectively. Results: The JAK2 V617F mutation was detected in 95.5%, 68.8%, and 52.9% of PV, ET, and PMF patients, respectively. JAK2 V617F-positive ET patients were significantly older and exhibited higher neutrophil fractions, a higher frequency of thrombotic events, and a higher myelofibrosis rate than JAK2 V617F-negative patients (P <0.05). PV patients carried the highest mean T allele burden (66.0%±24.9%) compared with ET (40.5%±25.2%) and PMF patients (31.5%±37.0%) (P =0.00). No significant correlations were detected between V617F allele burden and patient age, white blood cell count, Hb, Hct, or the platelet count for PV, ET, or PMF patients. ET patients with organomegaly had a higher JAK2 V617F allele burden (53.4%±23.7%) than patients without organomegaly (35.6%± 24.3%) (P =0.03). Conclusions: The JAK2 V617F mutational status and its allele burden correlate with the clinicohematologic phenotypes of ET patients, including older age, higher neutrophil count, and greater rates of organomegaly, thrombotic events, and myelofibrosis. For PV and PMF patients, larger-scale studies involving more MPN patients are needed.
참고문헌 (23)
- Tefferi A, "Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms", Leukemia, 22, pp.14~22 (2008)
- Kralovics R, "A gain-of-function mutation of JAK2 in myeloproliferative disorders", N Engl J Med, 352, pp.1779~1790 (2005)
- Baxter EJ, "Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders", Lancet, 365, pp.1054~1061 (2005)
- Campbell PJ, "Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study", Lancet, 366, pp.1945~1953 (2005)
- Wolanskyj AP, "JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance", Br J Haematol, 131, pp.208~213 (2005)
- Barosi G, "JAK2 V617F mutational status predicts progression to large splenomegaly and leukemic transformation in primary myelofibrosis", Blood, 110, pp.4030~4036 (2007)
- Rudzki Z, "The gain-of-function JAK2 V617F mutation shifts the phenotype of essential thrombocythemia and chronic idiopathic myelofibrosis to more “erythremic” and less “thrombocythemic”: a molecular, histologic, and clinical study", Int J Hematol, 86, pp.130~136 (2007)
- De Stefano V, "Increased risk of recurrent thrombosis in patients with essential thrombocythemia carrying the homozygous JAK2 V617F mutation", Ann Hematol, 89, pp.141~146 (2010)
- Silver RT, "JAK2(V617F) allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy", Leuk Res, 35, pp.177~182 (2011)
- Vannucchi AM, "Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden", Leukemia, 21, pp.1952~1959 (2007)
- Tefferi A, "The clinical phenotype of wild-type, heterozygous, and homozygous JAK2V617F in polycythemia vera", Cancer, 106, pp.631~635 (2006)
- Vannucchi AM, "Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia", Blood, 110, pp.840~846 (2007)
- Passamonti F, "A prospective study of 338 patients with polycythemia vera: the impact of JAK2 (V617F) allele burden and leukocytosis on fibrotic or leukemic disease transformation and vascular complications", Leukemia, 24, pp.1574~1579 (2010)
- Tefferi A, "Bone marrow JAK2V617F allele burden and clinical correlates in polycythemia vera", Leukemia, 21, pp.2074~2075 (2007)
- Antonioli E, "Clinical implications of the JAK2 V617F mutation in essential thrombocythemia", Leukemia, 19, pp.1847~1849 (2005)
- Antonioli E, "Influence of JAK2V617F allele burden on phenotype in essential thrombocythemia", Haematologica, 93, pp.41~48 (2008)
- Guglielmelli P, "Identification of patients with poorer survival in primary myelofibrosis based on the burden of JAK2V617F mutated allele", Blood, 114, pp.1477~1483 (2009)
- Campbell PJ, "V617F mutation in JAK2 is associated with poorer survival in idiopathic myelofibrosis", Blood, 107, pp.2098~2100 (2006)
- Delhommeau F, "Molecular aspects of myeloproliferative neoplasms", Int J Hematol, 91, pp.165~173 (2010)
- Passamonti F, "New generation small-molecule inhibitors in myeloproliferative neoplasms", Curr Opin Hematol, 19, pp.117~123 (2012)
- De Stefano V, "JAK2 V617F mutational frequency in essential thrombocythemia associated with splanchnic or cerebral vein thrombosis", Am J Hematol, 86, pp.526~528 (2011)
- Tefferi A, "The JAK2(V617F) tyrosine kinase mutation in myelofibrosis with myeloid metaplasia: lineage specificity and clinical correlates", Br J Haematol, 131, pp.320~328 (2005)
- Lasho TL, "Mutation studies in CD3+, CD19+ and CD34+ cell fractions in myeloproliferative disorders with homozygous JAK2(V617F) in granulocytes", Br J Haematol, 1, pp.797~799 (2005)